Effects of Intensive Antiplatelet Therapy for Patients With Clopidogrel Resistance After Coronary Stent Implantation

• Status: Completed
• Trial end date: 2012-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Clopidogrel resistance (CR) or low-responsiveness is associated with increased risk of ischemic events and can be detected by laboratory tests. This multicenter, randomized study is aimed to explore the efficacy and safety of intensive antiplatelet therapy (i.e. double clopidogrel maintenance dose and/or additional cilostazol)for patients with CR after coronary stenting.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shenyang Northern Hospital
• Treatments: Aspirin; Cilostazol; Clopidogrel; Ticlopidine

Criteria

Inclusion Criterial:

• aged 35 to 75 years

• acute coronary syndromes

• underwent successful coronary stent implantation

• informed consent

Exclusion Criteria:

• contraindications to antiplatelet therapy

• history of intracranial bleeding

• known bleeding disorders

• severe liver or kidney disease

• pregnancy

• left main coronary artery disease

• planned non cardiac surgery within 1 year

• end stage of other serious disease with life expectancy less than 1 year

• heart failure with NYHA grade 3 to 4